RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EPIRUS Biopharmaceuticals Stock

EPIRUS Biopharmaceuticals Debt 2024

EPIRUS Biopharmaceuticals Debt

0 USD

Ticker

EPRSQ

ISIN

US29428P1075

WKN

A117U3

In 2024, EPIRUS Biopharmaceuticals's total debt was 0 USD, a 0% change from the 0 USD total debt recorded in the previous year.

EPIRUS Biopharmaceuticals Aktienanalyse

What does EPIRUS Biopharmaceuticals do?

EPIRUS Biopharmaceuticals Inc is an American biotech company specializing in the development of innovative drugs for the treatment of cancer and autoimmune diseases. It was founded in 2010 by Amit Munshi and is headquartered in Boston, Massachusetts. The company's business model is based on the use of biotechnology and advanced research and development to create specialized medications. EPIRUS aims to help patients with serious medical needs and contribute to improving healthcare worldwide. EPIRUS Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding EPIRUS Biopharmaceuticals's Debt Structure

EPIRUS Biopharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing EPIRUS Biopharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to EPIRUS Biopharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in EPIRUS Biopharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about EPIRUS Biopharmaceuticals stock

What is the debt of EPIRUS Biopharmaceuticals this year?

EPIRUS Biopharmaceuticals has a debt level of 0 USD this year.

What was the debt of EPIRUS Biopharmaceuticals compared to the previous year?

The debt of EPIRUS Biopharmaceuticals has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in EPIRUS Biopharmaceuticals?

High debt can pose a risk for investors of EPIRUS Biopharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of EPIRUS Biopharmaceuticals?

Low debt means that EPIRUS Biopharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from EPIRUS Biopharmaceuticals affect the company?

An increase in debt of EPIRUS Biopharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of EPIRUS Biopharmaceuticals affect the company?

A reduction in debt of EPIRUS Biopharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of EPIRUS Biopharmaceuticals?

Some factors that can influence the debt of EPIRUS Biopharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of EPIRUS Biopharmaceuticals so important for investors?

The debts of EPIRUS Biopharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can EPIRUS Biopharmaceuticals take to change the debt?

To change the debt, EPIRUS Biopharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does EPIRUS Biopharmaceuticals pay?

Over the past 12 months, EPIRUS Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EPIRUS Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EPIRUS Biopharmaceuticals?

The current dividend yield of EPIRUS Biopharmaceuticals is .

When does EPIRUS Biopharmaceuticals pay dividends?

EPIRUS Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EPIRUS Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EPIRUS Biopharmaceuticals located?

EPIRUS Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EPIRUS Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EPIRUS Biopharmaceuticals from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did EPIRUS Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of EPIRUS Biopharmaceuticals in the year 2023?

In the year 2023, EPIRUS Biopharmaceuticals distributed 0 USD as dividends.

In which currency does EPIRUS Biopharmaceuticals pay out the dividend?

The dividends of EPIRUS Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EPIRUS Biopharmaceuticals

Our stock analysis for EPIRUS Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EPIRUS Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.